Ocugen (OCGN) Competitors $0.92 +0.04 (+4.55%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OCGN vs. LIFE, VIR, LENZ, IMTX, RLAY, CGEM, REPL, AUTL, CRGX, and AVXLShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include aTyr Pharma (LIFE), Vir Biotechnology (VIR), LENZ Therapeutics (LENZ), Immatics (IMTX), Relay Therapeutics (RLAY), Cullinan Therapeutics (CGEM), Replimune Group (REPL), Autolus Therapeutics (AUTL), CARGO Therapeutics (CRGX), and Anavex Life Sciences (AVXL). These companies are all part of the "biological products, except diagnostic" industry. Ocugen vs. aTyr Pharma Vir Biotechnology LENZ Therapeutics Immatics Relay Therapeutics Cullinan Therapeutics Replimune Group Autolus Therapeutics CARGO Therapeutics Anavex Life Sciences Ocugen (NASDAQ:OCGN) and aTyr Pharma (NASDAQ:LIFE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations. Does the MarketBeat Community believe in OCGN or LIFE? aTyr Pharma received 315 more outperform votes than Ocugen when rated by MarketBeat users. However, 69.93% of users gave Ocugen an outperform vote while only 59.77% of users gave aTyr Pharma an outperform vote. CompanyUnderperformOutperformOcugenOutperform Votes10769.93% Underperform Votes4630.07% aTyr PharmaOutperform Votes42259.77% Underperform Votes28440.23% Is OCGN or LIFE more profitable? aTyr Pharma has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. aTyr Pharma's return on equity of -56.92% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-532.51% -154.75% -90.79% aTyr Pharma N/A -56.92%-43.87% Does the media favor OCGN or LIFE? In the previous week, Ocugen had 10 more articles in the media than aTyr Pharma. MarketBeat recorded 15 mentions for Ocugen and 5 mentions for aTyr Pharma. Ocugen's average media sentiment score of 0.34 beat aTyr Pharma's score of 0.00 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, OCGN or LIFE? Ocugen has a beta of 3.75, suggesting that its stock price is 275% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Which has higher earnings and valuation, OCGN or LIFE? aTyr Pharma has lower revenue, but higher earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$6.04M44.30-$63.08M-$0.18-5.10aTyr Pharma$350K0.00-$50.39M-$0.90N/A Do insiders & institutionals have more ownership in OCGN or LIFE? 10.3% of Ocugen shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 4.3% of Ocugen shares are held by insiders. Comparatively, 3.7% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate OCGN or LIFE? Ocugen presently has a consensus target price of $5.67, suggesting a potential upside of 516.95%. aTyr Pharma has a consensus target price of $25.50, suggesting a potential upside of 0.00%. Given Ocugen's higher probable upside, equities research analysts plainly believe Ocugen is more favorable than aTyr Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOcugen beats aTyr Pharma on 9 of the 16 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$267.58M$2.93B$5.06B$8.82BDividend YieldN/A1.89%5.17%4.07%P/E Ratio-5.1045.62125.9917.81Price / Sales44.30359.341,180.3874.38Price / CashN/A160.0933.8232.53Price / Book5.743.734.684.68Net Income-$63.08M-$41.63M$119.54M$226.08M7 Day Performance-4.13%-7.95%-2.45%-2.04%1 Month Performance-2.29%-7.17%-4.06%0.06%1 Year Performance124.08%23.03%29.86%24.60% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.3147 of 5 stars$0.92+4.6%$5.67+516.9%+124.1%$254.50M$6.04M-5.1065Analyst ForecastLIFEaTyr Pharma1.7033 of 5 starsN/A$25.50+∞N/A$131.12M$350,000.00-2.1156Analyst ForecastVIRVir Biotechnology3.019 of 5 stars$6.74-2.7%$36.40+440.1%-31.2%$954.40M$86.18M0.00587Analyst ForecastLENZLENZ Therapeutics0.6564 of 5 stars$33.91-2.1%$35.40+4.4%N/A$952.91MN/A0.00N/AIMTXImmatics2.0118 of 5 stars$7.80-0.1%$16.67+113.7%-9.2%$930.98M$70.87M-8.76260Analyst ForecastNews CoverageRLAYRelay Therapeutics3.2712 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeCGEMCullinan Therapeutics1.8234 of 5 stars$12.58-4.0%$31.67+151.7%+43.6%$762.78M$18.94M0.0030Analyst RevisionREPLReplimune Group4.2366 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$749.17MN/A0.00210AUTLAutolus Therapeutics3.4682 of 5 stars$2.80-5.1%$10.15+262.5%-36.5%$745.05M$1.70M-2.31330Analyst UpgradeCRGXCARGO Therapeutics1.6683 of 5 stars$15.82-1.8%$30.33+91.7%+8.0%$741.51MN/A0.00116AVXLAnavex Life Sciences3.7023 of 5 stars$8.48+2.8%$40.00+372.0%+21.1%$718.68MN/A-16.9540Upcoming Earnings Related Companies and Tools Related Companies aTyr Pharma Alternatives Vir Biotechnology Alternatives LENZ Therapeutics Alternatives Immatics Alternatives Relay Therapeutics Alternatives Cullinan Therapeutics Alternatives Replimune Group Alternatives Autolus Therapeutics Alternatives CARGO Therapeutics Alternatives Anavex Life Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
